Results 81 to 90 of about 826,191 (386)

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Optimal conditions for slow passive release of heparin-binding growth factors from an affinity-based delivery system [PDF]

arXiv, 2011
We consider a mathematical model that describes the release of heparin-binding growth factors from an affinity-based delivery system. In the delivery system, heparin binds to a peptide which has been covalently cross-linked to a fibrin matrix. Growth factor in turn binds to the heparin, and growth factor release is governed by both binding and ...
arxiv  

Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington’s disease knock-in striatal cells [PDF]

, 2014
Akt, protein kinase B; ARE, antioxidant response element; Erk, extracellular signal-regulated kinase; CBP, CREB-binding protein; CREB, cAMP response-element (CRE) binding protein; CDK, cyclin-dependent kinase; DHE, dihydroethidium; Drp1, dynamin-related ...
Oliveira, Ana M., Oliveira, Catarina R., Rego, A. Cristina, Ribeiro, Márcio, Rosenstock, Tatiana R.   +4 more
core   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Insulin-like growth factor-I and its binding proteins in healthy mothers and their newborns [PDF]

Einstein (São Paulo), 2004
Objective: To determine serum levels of insulin-like growth factor-I, free insulin-like growth factor-I and its binding proteins in maternalserum and in cord blood of two groups of newborns with differentbirth weights.
Rosanna Velleca Lima, Daniel Giannella Neto, Conceição Aparecida de Mattos Segre, Saul Goldenberg   +3 more
doaj  

Insulin-Like Growth Factor-1 and Selected Insulin-Like Growth Factor Binding Protein Concentrations during an Ultramarathon Sled Dog Race

The Scientific World Journal, 2016
The objective of this study was to investigate the effects of running a 1000-mile (1600 km) endurance sled dog race on serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding proteins 1 and 3 (IGFBP-1 and IGFBP-3).
Matthew W. Brunke, Christopher W. Frye, Corri B. Levine, Cristina Hansen, Joseph J. Wakshlag   +4 more
doaj   +1 more source

Insulin-like growth factors in endometrioid adenocarcinoma: Correlation with clinico-pathological features and estrogen receptor expression

BMC Cancer, 2012
Background Endometrial carcinoma is a common malignancy of female genital tract. Insulin-like growth factor is known to elicit estrogen-induced mitogenic activity and anti-apoptotic effect in endometrial tissues.
Liang Yuan-Jiao, Hao Qun, Zhang Hui-Ming, Wu Yuan-Zhe, Wang Jian-Dong   +4 more
doaj   +1 more source

Insulin-Like Growth Factor and Lung Cancer [PDF]

Journal of Thoracic Oncology, 2006
Lung cancer is the leading cause of cancer-related death in the United States. Despite the availability of several cytotoxic and a few molecularly targeted agents, the outlook for patients with advanced non-small cell lung cancer continues to be dismal. Novel approaches are desperately needed.
Vamsidhar Velcheti, Ramaswamy Govindan
openaire   +3 more sources

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

Molecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte, Osheen Sharma, Laura Leuenberger, Emelie Wallin, Josefin Fernebro, Päivi Östling, Rebecka Bergström, Johan Lindberg, Ulrika Joneborg, Olli Kallioniemi, Brinton Seashore‐Ludlow   +10 more
wiley   +1 more source

Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-β) in normal vs cancerous breast epithelial cells [PDF]

In addition to modulating insulin-like growth factors action, it is now clear that insulin-like growth factor-binding protein-3 also has intrinsic effects on cell growth and survival.
AC Williams, AD Hollowood, AD Hollowood, AM Taylor, CA Fowler, CM Perks, CM Perks, CM Perks, CM Perks, CW Daniel, HD Soule, JI Jones, JL Martin, KL Schmeichel, KW Colston, LI Gold, M Reiss, MA Chrenek, ME Yateman, P Cohen, R Rajah, S Fanayan, S Kansra, SC Davies, SM Leal, Y Oh, Y Oh, Y Oh, Z Pietrzkowski, ZP Gill   +29 more
core   +2 more sources